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Stlrnrnal-y 
Interleukin 10 (IL-10) has been shown to inhibit endotoxin-induced tumor necrosis factor (TNF) 
production.  To assess the role of TNF in the induction of IL-IO in endotoxemia,  four healthy 
men were studied after a bolus intravenous injection of recombinant human TNF (50/~g/m2). 
In addition,  13 healthy chimpanzees  were investigated after a bolus intravenous injection of Escherichia 
coli endotoxin (4 ng/kg),  6 animals received endotoxin only, 4 animals received a simultaneous 
intravenous injection of a monoclonal anti-TNF  antibody, whereas 3 chimpanzees were treated 
with an anti-TNF F(ab')2 fragment 30 min after the administration  of endotoxin. TNF induced 
a modest rise in IL-10 concentrations peaking after 45 min (47  +  32 pg/ml; p  <0.05).  IL-IO 
peaked 2 h after injection of endotoxin (202  +  61 pg/ml; p <(0.005).  In both anti-TNF-treated 
groups,  the early endotoxin-induced  TNF  activity was completely neutralized.  Simultaneous 
anti-TNF treatment attenuated endotoxin-induced IL-10 release (73  _+  13 pg/ml; p <0.01 versus 
endotoxin alone),  whereas postponed anti-TNF treatment did not significantly affect this response 
(p =  0.21). These results indicate that TNF, in part, mediates the induction of IL-10 in endotoxemia, 
resulting  in  an autoregulatory  feedback loop. 
T 
NF is considered to occupy a central role in the patho- 
genesis of sepsis (1). In experimental sepsis, TNF is the 
first cytokine appearing in the circulation, and neutralization 
of this  early TNF  activity markedly reduces mortality  as- 
sociated with the intravenous administration  of living bac- 
teria (1, 2). In accordance,  high levels of TNF have been found 
in the circulation of patients with sepsis (3, 4), and adminis- 
tration of the recombinant  cytokine to animals  or humans 
causes pathological  changes also observed in clinical  sepsis 
(5,  6). 
IL-10 is a recently discovered cytokine that  can he pro- 
duced by a variety of cell types, including T  cells,  B cells, 
monocytes, and macrophages (7). Incubation of monocytes 
or human whole blood with endotoxin results in the produc- 
tion of TNF,  followed by that  of IL-10 (8,  9).  In patients 
with sepsis,  the serum concentrations  of IL-10 are elevated 
(9). Several lines of evidence indicate that this induced IL-10 
is part of an endogenous protective mechanism that involves 
inhibition of TNF production. First,  IL-10 inhibits endotoxin- 
induced TNF release  by mononuclear  cells in vitro and in 
mice in vivo (8,  10-12).  Second, neutralization  of endoge- 
nous IL-10 potentiates endotoxin-induced TNF production 
by mononuclear cells (8, 9), and in intact mice (13, 14). Fi- 
nally,  administration  of IL-10 to  mice reduces endotoxin- 
induced  lethality  (11, 12),  whereas  passive  immunization 
against IL-10 enhances lethality associated with the adminis- 
tration  of endotoxin  (13,  14). 
It is interesting to note that a recent study has implicated 
TNF as a regulator of IL-10 expression by mononuclear cells 
in vitro, suggestive of the existence of an autoregulatory feed- 
back mechanism  (15).  Therefore,  in  the present  study we 
sought to determine whether TNF is involved in the appear- 
ance of endotoxin-induced  IL-10 in vivo. 
Materials and Methods 
Study Design.  Four healthy men (27-33-yr-old) received a bolus 
intravenous  injection  of human  recombinant  TNF  (50 #g/m2; 
Boehringer  Ingelheim,  Ingelheim am Rhein, Germany). Details 
of the experimental procedures and outcomes of clinical parameters 
have been published previously (6). In addition,  13 healthy adult 
chimpanzees, recruited from the primate colony at the Laboratory 
for Experimental  Medicine and Surgery in Primates, New York 
University  School of Medicine (Tuxedo, NY) were studied after 
a bolus intravenous injection ofEsche6chia coli endotoxin (4 ng/kg; 
lot EC-5, kindly provided by Dr. H. D. Hochstein, Food and Drug 
Administration, Bethesda, MD). The experimental procedures have 
been reported in detail previously (16, 17). Briefly, the chimpanzees 
were  sedated with  ketamin  chloride  and  intubated.  General 
anesthesia was maintained with nitrous oxide and halothane until 
the end of the study. Vital functions were registered during the 
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serious clinical effects, and all animals fully recovered from the ex- 
periment (16,  17). Six animals received only the bolus injection 
of purified endotoxin. In four animals the injection of endotoxin  ~  60 
was immediately followed by the administration of antioTNF mAb 
(provided by Bayer, Wuppertal, Germany) given as a bolus injec-  40 
tion of 15 mg/kg body weight (16). In three chimpanzees, the ad-  o 
ministration of endotoxin was followed after 30 min by the ad-  , 
ministration  of  an  anti-TNF  F(ab')2  fragment  (MAK  195F;  20 
provided by Knoll, Ludwigshafen, Germany) given as a bolus in- 
jection of 0.1  mg/kg body weight.  MAK 195F is derived from  0 
a murine TNF neutralizing mAb (IgG3) produced with standard 
methods using hybridoma cell cultures  (18).  A F(ab')2 fragment 
was made by removing the Fc portion of the antibody by enzy- 
matic cleavage with pepsin. Both the anti-TNF mAb and the anti- 
TNF F(ab')~ fragment potently neutralize human and chimpanzee 
TNF, and have no cross-reactivity with a series of other cytokines, 
including lymphotoxin (16,  18). 
Sampling and Assays.  From the human volunteers, blood was 
drawn directly before the administration of recombinant TNF and 
at 0.25, 0.5, 0.75,  1, 2, 3, 4, and 5 h thereafter. From the chim- 
panzees, blood was obtained for measurement of IL-10 directly be- 
fore the injection of endotoxin and at 1, 2, 3, 4, and 5 h thereafter. 
IL-10 was measured by ELISA. Microtiter plates were coated over- 
night at 4~  with anti-IL-10  mAb JES3-9D7 (Pharmingen,  San 
Diego, CA; 1/~g/ml in 0.1 M bicarbonate buffer, pH 9.6).  After 
washing and blocking the plates with 1% BSA in PBS, standards 
(recombinant  human  IL-10; Medgenix,  Fleurus,  Belgium)  and 
samples, diluted at least 1:1 in assay buffer (Central Laboratory of 
the Netherlands Red Cross Blood Transfusion Service, Amsterdam, 
the Netherlands), were incubated for 1 h at room temperature. After 
washing,  biotinylated anti-IL-10  mAb JES3-12G8 (Pharmingen), 
1/~g/ml in assay buffer, containing 2.5% normal rat serum (GIBCO, 
Life Technologies, Paisley, UK), was added and incubated for 1 h 
at room temperature. Thereafter, the wells were washed again and 
horseradish  peroxidase  conjugated  to  streptavidin  (poly-HRP- 
streptavidin;  Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service) was added (final concentration 1:10,000 in assay 
buffer) and allowed to incubate for 1 h at room temperature. After 
washing,  ortho-phenylenediamine-dihydrochloride  substrate was 
added and incubated for 30 min. The reaction was stopped with  2s0 
H2S04 and read at 490 nm. The detection limit of the assay was 
5 pg/ml. In the chimpanzees, serum TNF was measured both with  -~  200 
an immunological assay (IRMA; Medgenix) that detects total TNF 
irrespective of its binding to soluble receptors (19), and with a bio-  t~  O.  150 
logical assay using WEHI-164 mouse fibrosarcoma cells (20). Cy-  o 
totoxicity was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-  '7  10o 
diphenyl tetrazolium bromide (MTT) cytotoxicity assay. Concen-  ..a 
trations of TNF activity are given in picograms per milliliter using  50 
recombinant human TNF (Cetus, Emeryville, CA) as the standard. 
All samples were stored at  -70~  until assays were performed.  0 
StatisticalAnalysis.  All values are given as means +  SEM. Differ- 
ences in results within and between groups were analyzed by anal- 
ysis of variance. Correlations were calculated  with the Pearson test. 
p  <.05  was considered to represent a significant difference. 
Results 
Injection of TNF into Humans.  At baseline, IL-10 was not 
detectable in any of the human volunteers.  TNF  induced  a 
transient rise in circulating IL-10 concentrations (Fig. 1). IL-IO 
peaked after 45 rain (47  _+ 32 pg/ml; p <0.05 versus baseline). 
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Figure  1.  Mean  (_+ SE) plasma concentrations of Ibl0 after an intrave- 
nous bolus injection of recombinant human TNF (50/zg/m  2) into four 
healthy humans. TNF induced a significant increase in IL-10  levels (p <0.001 
by analysis of variance). 
Anti-TNF  in Chimpanzee Endotoxemia.  Administration 
of endotoxin  to the chimpanzees resulted in a transient  in- 
crease in serum TNF immunoreactivity and bioactivity, both 
reaching a summit after 1.5 h  (192  _+  76 pg/ml and 150  _+ 
46 pg/ml,  respectively; both p  <0.005  versus baseline).  En- 
dotoxin administration  was also associated with a transient 
rise in IL-10 concentrations in the circulation (Fig. 2). Peak 
IL-10 levels were reached after 2 h (202  _+ 61 pg/ml; p <0.005 
versus baseline) and showed a significant negative correlation 
with peak immunoreactive TNF concentrations (r =  -0.85, 
p  <0.05;  Fig.  3),  supporting  earlier  studies  demonstrating 
that endogenous IL-10 inhibits endotoxin-induced  TNF re- 
lease in  mice (13,  14). 
Both anti-TNF strategies used, i.e.,  simultaneous treatment 
with  an anti-TNF  mAb and  treatment  with  an  anti-TNF 
1 
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Figure  2.  Mean  (_+ SE) serum concentrations of IL-10 in chimpanzees 
intravenously injected with a bolus dose ofE. coli  endotoxin alone (4 ng/kg; 
e; n =  6), with endotoxin and a simultaneous intravenous injection of 
an anti-TNF mAb (O; n =  4), or with endotoxin followed after 30 min 
by an intravenous injection of an anti-TNF F(ab')2 fragment (f-q; n = 3). 
Simultaneous injection of anti-TNF significantly  attenuated the endotoxin- 
rise in IL-10 concentrations (p <0.01 versus endotoxin alone by analysis 
of variance), whereas postponed treatment with anti-TNF did not (p = 
0.21). 
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Figure 3.  Correlation  between peak IL-10 and peak TNF concentra- 
tions in six chimpanzees intravenously injected with E. coli endotoxin 
(4 ng/kg). 
F(ab')2 fragment administered 30 min after the injection of 
endotoxin, completely prevented the appearance  of TNF bio- 
activity in the circulation  (both p  <0.01  versus endotoxin 
alone).  In  addition,  in  all  anti-TNF-treated  animals,  im- 
munoreactive TNF remained undetectable,  indicating  that 
the in  vivo-administered  antibodies  bind  to  epitopes that 
overlap with those bound by the antibodies used in the im- 
munoassay. In the chimpanzees that were injected simultane- 
ously with  endotoxin  and anti-TNF,  the increase in IL-10 
was  significantly  attenuated  (p  <0.005  versus  endotoxin 
alone), and maximal IL-10 levels (73  _+ 13 pg/ml) were reached 
1 h later when compared with administration  of endotoxin 
alone (Fig. 2). In contrast, in the animals in which anti-TNF 
treatment was postponed for 30 rain after endotoxin injec- 
tion, neither the peak IL-10 response, nor the kinetics of the 
IL-10 response was significantly altered. In this group, peak 
IL-10 concentrations were found after 2 h (199  +  84 pg/ml; 
p  =  0.21 versus endotoxin  alone;  Fig.  2). 
Discussion 
The capability of IL-10 to inhibit endotoxin-induced TNF 
production has been carefully documented (8, 10-12). Inves- 
tigations with antibodies against IL-10 have revealed that IL-10 
negatively controls TNF synthesis in endotoxemia (13, 14). 
The present study shows that TNF produced early after ad- 
ministration of endotoxin to chimpanzees contributes to the 
later appearance of IL-10.  Hence, in endotoxemia,  TNF is 
involved in the induction of a cytokine that provides a nega- 
tive feedback to its own production. 
Injection of recombinant TNF into normal humans resulted 
in a rapid release of IL-10 into the circulation. To our knowl- 
edge, only one study has reported the ability of TNF to stimu- 
late IL-10 production to date. In that investigation, TNF was 
shown to be unique among a number of proinflammatory 
cytokines, including  IL-1  and IL-6,  in upregulating  IL-10 
expression in PBMC in vitro (15). TNF induced IL-10 mRNA 
in a dose-dependent manner, an effect that was detected after 
incubation with TNF for 24 h.  Incubations for up to 8 h 
did not result in significant IL-10 mR.NA induction, which 
contrasts with the present in vivo finding that demonstrates 
maximal IL-10 induction within 45 min after TNF adminis- 
tration. 
After injection of endotoxin, peak IL-10 levels were reached 
1 h later than after administration of TNF. These differential 
time frames suggested that TNF may be involved in endo- 
toxin-induced  IL-10 production.  Indeed,  simultaneous  ad- 
ministration  of anti-TNF  importantly  reduced the appear- 
ance of IL-10 in endotoxemia. It is notable that the capacity 
of TNF to induce IL-10 production may be enhanced in en- 
dotoxemia,  since TNF has been shown to potentiate endo- 
toxin-induced IL-10 synthesis by mononuclear cells in vitro 
(15). It is remarkable that delayed treatment with anti-TNF 
did not significantly affect IL-10 induction after endotoxin 
injection, in spite of the fact that it still completely prevented 
the appearance of TNF activity in the circulation. This sug- 
gests that within 30 rain after injection of endotoxin, some 
TNF is induced at tissue level and/or in cell-associated form 
that  contributes  to the  synthesis of IL-10,  possibly syner- 
gizing with endotoxin  (15) or yet unidentified  factors.  In- 
deed, studies in rodents have revealed that endotoxin induces 
a very rapid expression of the TNF gene in vivo, with TNF 
mKNA levels peaking in various organs as early as 15 min 
after the administration  of endotoxin  (21). 
Enhanced production of IL-10 in endotoxemia and sepsis 
likely represents an attempt of the host to counteract exces- 
sive activity of proinflammatory cytokines. The proximal role 
of TNF in the induction  of the proinflammatory cytokine 
cascade  in gram-negative infection  has been widely recog- 
nized (1, 2, 16). Our study demonstrates that TNF is capable 
of eliciting IL-10 release,  and that endogenous TNF has an 
important role in ILol0 secretion in endotoxemia. These data 
suggest that in endotoxemia TNF contributes to the produc- 
tion of an important antiinflammatory cytokine that at least, 
in part,  functions  to inhibit  ongoing TNF  synthesis. 
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